New meningitis vaccine trial aims to shield babies from deadly infection

NCT ID NCT07505810

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Sinovac Biotech Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 11, 2026 · Updated 4 times

Summary

This Phase 3 trial tests a new vaccine designed to protect infants aged 3 to 5 months against four strains of meningococcal bacteria that cause meningitis and sepsis. About 880 healthy babies will receive either the experimental vaccine or a licensed comparator vaccine. Researchers will measure immune response and safety after the initial three-dose series and a booster at 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Group ACYW135 Meningococcal Conjugate Vaccine
What this could lead to: If successful, this vaccine could protect infants from four types of meningococcal bacteria that cause meningitis and bloodstream infections.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet available. The vaccine may not prove as effective or safe as the existing licensed vaccine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPIDEMIC MENINGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningitis meningococcal meningitis meningococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPIDEMIC MENINGITIS MENINGOCOCCAL VACCINES

Contacts and locations

Locations

Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
RECRUITING

Nanning, Guangxi, 530028, China
Shanxi Provincial Center for Disease Control and Prevention
RECRUITING

Taiyuan, Shanxi, 030032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.